Correlation of parasite load determined by quantitative PCR to clinical outcome in a heart transplant patient with disseminated toxoplasmosis.
Disseminated toxoplasmosis is a life-threatening infection in transplant recipients, which results either from reactivation of latent infection or from organ-transmitted primary infection. Preventive measures and diagnostic screening methods differ between countries and are related to the seroprevalence of Toxoplasma spp. in the general population. Here we report a case of disseminated toxoplasmosis in a heart transplant recipient with previous immunity that occurred after cotrimoxazole prophylaxis for the prevention of Pneumocystis jirovecii pneumonia was stopped. Quantitative PCR proved useful for the diagnosis and monitoring of Toxoplasma infection. Decreasing parasitic burdens in sequential samples of cerebrospinal fluid, blood, and bronchoalveolar lavage fluid correlated with a favorable outcome and allowed modulation of the immunosuppressive drug regimen. The duration of anti-Toxoplasma treatment and the need for maintenance prophylaxis are discussed, as well as prophylaxis for solid-organ transplant recipients. Although a rare event in heart transplant recipients, Toxoplasma reactivation must be investigated promptly, since early treatment improves the prognosis.
Patrat-Delon
Solène
S
Service de Réanimation Médicale et Maladies Infectieuses, Centre Hospitalier et Universitaire de Rennes, Rennes, France.
Gangneux
Jean-Pierre
JP
Lavoué
Sylvain
S
Lelong
Bernard
B
Guiguen
Claude
C
le Tulzo
Yves
Y
Robert-Gangneux
Florence
F
D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000913:Antibodies, Protozoan; D016054:DNA, Protozoan / Q000032:analysis*; D016027:Heart Transplantation; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D008297:Male; D051379:Mice; D008875:Middle Aged; D016133:Polymerase Chain Reaction / Q000379:methods*; D014122:Toxoplasma / Q000235:genetics / Q000302:isolation & purification; D014123:Toxoplasmosis / Q000175:diagnosis* / Q000188:drug therapy / Q000469:parasitology; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
D000890:Anti-Infective Agents; D000913:Antibodies, Protozoan; D016054:DNA, Protozoan; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
Transpl Int. 2000;13(6):448-52
11140244
Pediatr Infect Dis J. 2010 Jan;29(1):33-8
19858771
Transplantation. 2003 Feb 15;75(3):339-43
12589155
Transpl Infect Dis. 2002 Jun;4(2):93-6
12220246
Clin Ther. 1996 Nov-Dec;18(6):1037-56; discussion 1036
9001822
Transpl Immunol. 2007 Nov;18(2):193-7
18005867
Clin Infect Dis. 2001 Jul 1;33 Suppl 1:S26-31
11389519
Clin Infect Dis. 2009 Jan 15;48(2):e9-e15
19072243
Clin Infect Dis. 1992 Aug;15(2):267-70
1520761
J Infect. 1994 Nov;29(3):249-53
7884217
Bone Marrow Transplant. 2010 Mar;45(3):580-3
19597419
Clin Infect Dis. 1992 Apr;14(4):847-51
1576279
Clin Infect Dis. 2005 Jan 1;40(1):67-78
15614694
Transpl Infect Dis. 2008 Feb;10(1):71-4
17605745
Clin Infect Dis. 2003 Apr 1;36(7):932-3; author reply 933
12652396
Transpl Infect Dis. 2005 Mar;7(1):38-40
15984948
J Heart Lung Transplant. 2006 Nov;25(11):1380-2
17097506
J Clin Microbiol. 2002 May;40(5):1648-50
11980935
Eur J Clin Microbiol Infect Dis. 2002 May;21(5):353-61
12072919
Bone Marrow Transplant. 1994 Aug;14(2):241-5
7994239
J Infect Dis. 2009 Apr 15;199(8):1155-67
19265484
Clin Microbiol Infect. 2008 Dec;14(12):1089-101
19018809
Pediatr Blood Cancer. 2007 Feb;48(2):222-6
16333839
J Clin Microbiol. 2003 Nov;41(11):5313-6
14605193
J Clin Microbiol. 2005 Jul;43(7):3544-7
16000502
Eur J Clin Microbiol Infect Dis. 2000 Feb;19(2):89-95
10746493
J Clin Pathol. 1989 Feb;42(2):194-9
2493490
Transplantation. 2008 Apr 15;85(7):980-5
18408578
Transpl Infect Dis. 2000 Sep;2(3):127-32
11429023
Am J Trop Med Hyg. 2009 Apr;80(4):583-7
19346380
Ann Intern Med. 1983 Jul;99(1):27-31
6344718
Eur J Clin Microbiol Infect Dis. 1996 May;15(5):389-93
8793397
Clin Infect Dis. 2001 Sep 1;33(5):629-40
11486285